Understanding the effect of cannabidiol (CBD) on brain function
This research uses brain imaging (MRI) to compare the brains of individuals without hallucinations or delusions to those with Parkinson’s psychosis treated with cannabidiol (CBD) in the CAN-PDP trial.
It aims to improve understanding of CBD's effects on how the brain works.
• 44 people with Parkinson’s psychosis. This could include seeing, hearing, or feeling things that aren’t there and mistaking objects for other things (hallucinations). For example, a pile of clothes might look like a dog. Symptoms could also include unusual thoughts, beliefs, or worries that aren't based on reality (delusions).
• 21 people with Parkinson's who don't experience psychosis
• 21 people without Parkinson’s
The researchers are looking for people who are 40 years old or older and are not participating in any clinical trial involving taking a study medication.
You will be asked to attend 1 study visit at King's College Hospital in London, which will last for 2 to 4 hours.
You will take part in various assessments, including surveys and an MRI scan. You will not receive a study drug, CBD or placebo (dummy drug).
Travel expenses will be reimbursed.
For more information, please read the:
• participant information sheet for people with Parkinson’s psychosis
Interested in taking part?
Contact the research team by email at [email protected], or call: 07936 545 178.
The deadline for taking part in this research is 1 October 2026.
Parkinson's UK
Kings College Hospital
Kings College Hospital
Denmark Hill
London
SE5 8AF
United Kingdom